![]() |
市場調查報告書
商品編碼
1636045
2025-2033年按病毒類型(基因工程溶瘤病毒、溶瘤野生型病毒)、應用(實體瘤、黑色素瘤)、最終用途(醫院、專科診所、癌症研究所)及地區分類的溶瘤病毒療法市場報告Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2025-2033 |
2024年全球溶瘤病毒療法市場規模達1.908IMARC Group美元。
溶瘤病毒療法是一種利用病毒感染和破壞癌細胞的免疫療法。他們使用各種天然和基因改造病毒,如單純皰疹病毒、新城疫病毒、痘苗病毒、腺病毒、呼腸孤病毒和小核糖核酸病毒。溶瘤病毒療法會活化危險訊號以產生免疫反應,並廣泛用於治療實體瘤、黑色素瘤和不可切除的病灶。它們還使用僅感染和破壞目標腫瘤細胞的病毒來幫助根除腫瘤。與化療相比,溶瘤病毒療法無毒,療效優越,可延長癌症患者的存活期。因此,它們在醫院、診所和癌症研究機構中得到了廣泛的應用。
全球癌症發生率的上升為市場創造了積極的前景。溶瘤病毒療法因其強大的抗腫瘤特性以及在不傷害周圍組織的情況下準確靶向腫瘤的能力而被廣泛用於治療各種癌症,例如膠質母細胞瘤、乳腺癌、肺癌和前列腺癌。與此一致的是,該療法廣泛用於治療各種類型的黑色素瘤,如血液惡性腫瘤、淋巴瘤、白血病和骨髓瘤,有利於市場成長。此外,患者對手術介入、放射治療、化療和免疫療法等各種癌症治療對健康的負面影響日益擔憂,這極大地推動了市場成長。此外,越來越多的溶瘤病毒(例如皰疹病毒、腺病毒和牛痘病毒)臨床研究數量不斷增加,這些研究已處於最後階段,並已證明了良好的實驗結果,正在促進市場成長。其他因素,包括對先進治療和新療法的需求不斷成長,以及多個政府為提高對不同癌症原因的認知並促進早期診斷而採取的更多舉措,預計將推動市場成長。
The global oncolytic virus therapies market size reached USD 190.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 797.9 Million by 2033, exhibiting a growth rate (CAGR) of 16.37% during 2025-2033.
Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.
The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.
Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Adenovirus
Vaccinia Virus
Oncolytic Wild-Type Viruses
Reovirus
Newcastle Disease Virus
Vesicular Stomatitis Virus
Solid Tumors
Breast Cancer
Prostate Cancer
Lung Cancer
Glioblastoma
Melanoma
Hematological Malignancies
Lymphoma
Leukemia
Myeloma
Hospitals
Specialty Clinics
Cancer Research Institute
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.